Recombinant Human TFF2 Protein

Beta LifeScience SKU/CAT #: BLA-8915P

Recombinant Human TFF2 Protein

Beta LifeScience SKU/CAT #: BLA-8915P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Host Species Human
Accession Q03403
Synonym SML 1 SML1 SP Spasmolysin Spasmolytic polypeptide spasmolytic protein 1 TFF 2 TFF2 TFF2_HUMAN Trefoil factor 2 trefoil factor 2 (spasmolytic protein 1) Trefoil factor 2 precursor
Description Recombinant Human TFF2 Protein was expressed in E.coli. It is a Full length protein
Source E.coli
Molecular Weight 12 kDa
Purity >97% SDS-PAGE.>97% as determined by SDS-PAGE and HPLC.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity Fully biologically active when compared to standard. The ED50 as determined by a chemotaxis bioassay using human MCF-7 cells is less than 10 ng/ml, corresponding to a specific activity of >1.0x105 IU/mg.
Formulation Lyophilised
Stability The recombinant protein samples are stable for up to 12 months at -80°C
Reconstitution See related COA
Unit Definition For Research Use Only
Storage Buffer Shipped at 4°C. Store at -80°C. Avoid freeze / thaw cycle.

Target Details

Target Function Inhibits gastrointestinal motility and gastric acid secretion. Could function as a structural component of gastric mucus, possibly by stabilizing glycoproteins in the mucus gel through interactions with carbohydrate side chains.
Subcellular Location Secreted.
Database References
Tissue Specificity Stomach.

Gene Functions References

  1. Data show that trefoil factor 2 (TFF2( urine levels continuously decreased with disease progression, TFF2 serum concentrations progressively increased from the early to later chronic kidney disease (CKD) stages, indicating changes in renal function and offering the potential to examine the course of CKD. PMID: 28355260
  2. this work reveals that TFF2 has tumor-suppressor activity, which may, in part, be regulated by SMAD4. PMID: 27523981
  3. Data show the important functions of TFF2 in the gastric mucus barrier, mucus epithelia, immune system, central nervous system, and during fertilization. It has been shown to interact with the gastric mucin MUC6. [Review] PMID: 26201258
  4. We reproducibly associate higher expression of the ligand-receptor axis of TFF2 and CXCR4 with BRAF V600E-mutant colon cancer PMID: 25899003
  5. protease-activated receptor 4 and Trefoil factor 2 are expressed in human colorectal cancer PMID: 25876034
  6. The structural features of the N-linked N,N'-di-N-acetyllactosediamine-inducing determinant on human TFF2 are discussed. PMID: 25210040
  7. Human TTF2 is a lectin that binds alpha-GlcNAc-capped mucin 6 g with antibiotic activity against Helicobacter pylori. PMID: 25124036
  8. Significantly higher levels of TFF2 were in patients with Multiple Organ Dysfunction Syndrome. PMID: 23628371
  9. There is an association between TFF2 and TFF3 polymorphisms and risk of atrophic gastritis and gastric cancer in Chinese people. PMID: 23933418
  10. Human gastric TFF2 peptide contains an N-linked fucosylated N,N'-diacetyllactosediamine (LacdiNAc) oligosaccharide PMID: 22997242
  11. Report TFF2 expression in normal/diseased pancreas and suggest role in tumor cell migration. PMID: 22286382
  12. Report a novel TFF2 splice variant (EX2TFF2) which correlates with longer overall survival time in cholangiocarcinoma. PMID: 22159958
  13. TFF2 messenger RNA expression is significantly increased in nasal mucosal brushings during asthma exacerbations in children. PMID: 22329990
  14. Data show that frog TFF2 activates protease-activated receptor (PAR) 1 to induce human platelet aggregation, and suggest that human TFF2 promotes cell migration via PAR4. PMID: 21461878
  15. TFF2 is mitogenic in cholangiocarcinoma via EGFR/MAPK activation. PMID: 21472131
  16. TFF2 negatively regulates preneoplastic progression and subsequent tumor development in the stomach, a role that is subverted by promoter methylation during H pylori infection PMID: 20801119
  17. autoinduction of promoter requires an upstream cis-acting element PMID: 12054609
  18. Transcripts not detectable in conjunctiva. Review. PMID: 12613926
  19. expression of TFF2 and Helicobacter pylori infection in carcinogenesis of gastric mucosa PMID: 12717829
  20. The results suggest that TFF2 expression may play a role in gastric cancer invasion and could be a useful target for therapeutic intervention. PMID: 13679442
  21. PPARgamma mediates NSAIDs-induced up-regulation of TFF2 expression in gastric epithelial cells. PMID: 14759512
  22. TFF2 and its putative receptor, DMBT1, were expressed non-specifically in biliary epithelial cells of the damaged small bile ducts, suggesting a cytoprotective role in biliary pathophysiology. PMID: 15101998
  23. TFF2 could play a role in mammary gland tumorigenesis. PMID: 15177880
  24. TFF2 is expressed in normal and malignant breast epithelial cells and it stimulates the migration of breast cancer cells. PMID: 15177883
  25. Epidermal growth factor and trefoil factor family 2 synergistically trigger chemotaxis on BEAS-2B cells via different signaling cascades PMID: 15256384
  26. Demonstration that TFF2 rhythm is impaired in cohorts of individuals known to suffer gastric symptoms suggests that interventions to restore the normal TFF2 rhythm in those with poor mucosal protection could reduce morbidity. PMID: 15984970
  27. TFF2 staining was detected in large, diffuse tumors and in tumors with lymph node metastasis and had a significant correlation with the number of microvessels. PMID: 16166422
  28. human pancreatic polypeptide inhibits TFF2 secretion in a diurnal rhythm PMID: 16359755
  29. Co-localization of TFF2 with gland mucous cell mucin suggests a physical interaction between TFF2 and gland mucous cell mucin. The TFF2 trapped in the adherent mucins may be responsible for mucosal defense, healing, and repair. PMID: 16786324
  30. PPARgamma may be involved in the gastric mucosal defense through regulating TFF2 expression PMID: 17118693
  31. Gastrin regulates TFF2 transcription through a GC-rich DNA-binding site and a protein kinase dependent pathway. PMID: 17332476
  32. CXCR4 as a bona fide signaling receptor for TFF2 and suggest a mechanism through which TFF2 may modulate immune and tumorigenic responses in vivo. PMID: 19064997
  33. The researchers found evidence that H. pylori-associated CAG has a negative effect on the expression of TFF2 in the gastric antrum and may be associated with H. pylori-induced gastric mucosal damage. PMID: 19344006
  34. p53 induces cell apoptosis and inhibits cell migration in part by downregulating TFF2 expression through an AP-1-like site, suggesting that TFF2 may be an important downstream target of p53. PMID: 19541923


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed